Efanesoctocog alfa

The bleeding disorder-specific corporate reputation results are in, and Sobi has landed the top spot. That’s according to PatientView’s annual corporate reputation survey (PDF) for 2025/2026, which drew its results after polling 65 bleeding disorder patient groups across 31 countries between December 2025 and March 2026. Respondents were asked to weigh nine bleeding disorder companies across several different factors to determine which have the highest reputation between Bayer, BioMarin, CSL Behring, Novo Nordisk, Pfizer, Sanofi, Sobi, Takeda and Roche and its subsidiaries Genentech and Chugai Pharmaceutical. The top three showed no difference between the two categories PatientView uses to differentiate companies that respondents have worked with firsthand or companies that respondents are familiar with. For both categories, Sobi topped the list at No. 1, while Roche/Genentech/Chugai came in second and Novo took third. Although they didn’t make the top three this year, two companies still notably climbed the ranks in Sanofi and CSL Behring. Sanofi took the crown for the fastest-rising company in the group of drugmakers respondents were familiar with, zooming up two places from its last ranking. CSL Behring, meanwhile, jumped up a spot when ranked by respondents who have experience working with the company. The bleeding disorder patient groups, which together supported 204,000 patients over the last year, made their picks based on a wide set of indicators of corporate reputation, including safety, pricing transparency, equitable access and integrity. Over the past five years since PatientView’s 2021/2022 survey, the patient groups view of the corporate reputation of the pharma industry as a whole has declined. Specific areas in which the industry weakened over that timeframe, according to the respondents, lay in access to medicines, services ‘beyond the pill’, patient engagement in R&D and the provision of patient information. However, the patient groups also reported boosts in transparency in clinical data, innovation ability, commitment to patient safety and more, while “slight” increases were perceived in fair pricing policies, price transparency and products of benefit to patients with bleeding disorders. “Our needs regarding our entire population have not been met yet, although we have preventative treatment for all patients through the Unified Health System/SUS [Sistema Único de Saúde, the National Health System of Brazil],” one bleeding disorders patient group out of Brazil commented in PatientView’s press release. Sobi and Roche’s corporate reputations have earned high marks as of late, with Sobi nabbing the top spot for overall corporate reputation in rare disease in 2024. In that report, Roche took second place under Sobi as ranked by 518 rare disease patient groups. Roche also claimed the No. 1 spot when it comes to cancer rankings in a recent PatientView report released last week. Swedish pharma Sobi’s biggest drug sector is hematology, where it markets a number of bleeding disorder drugs including Sanofi-partnered Altuviiio and Eloctate, both of which treat hemophilia A. Roche, for its part, sells hemophilia A mainstay Hemlibra, which remains a top growth driver for the company.

After a site visit by FDA inspectors yielded a Form 483 for Genzyme Ireland in early 2026, the Sanofi subsidiary is facing further reprimand from the U.S. regulator. Sanofi’s long-held Genzyme unit has now received the more serious wrist slap of a warning letter from the FDA, after agency officials visited the Sanofi site in Waterford, Ireland, between Jan. 12 and Jan. 20 this year. The site inspection uncovered what the FDA has branded “significant” manufacturing violations tied to Sanofi’s Thymoglobulin (Anti-thymocyte Globulin [Rabbit]) product— indicated to prevent and treat acute rejection in kidney transplant patients—as well as its Sobi-partnered hemophilia A drug Altuviiio. In an emailed statement, a Sanofi spokesperson stressed to Fierce that “patient safety and the quality of our products are our highest priorities.” “We take the FDA Warning Letter issued to the Waterford facility with the utmost seriousness,” the spokesperson continued. “We are taking immediate actions and are committed to fully addressing each of the Agency’s observations, robustly and sustainably.” Following receipt of the Form 483 at the Ireland site earlier this year, Sanofi responded to the FDA’s concerns in February, again following up in April. The FDA conceded in its warning letter that Sanofi’s responses pointed to “corrective actions to address each individual Form-483 observation.” However, the agency argued that the reply still neglected to address the “underlying failure” of the site’s quality unit to meet current manufacturing standards. The FDA also suggested that several responses Sanofi proposed may be inadequate, with the crux of its argument suggesting that the site fumbles to “demonstrate a pattern in which your quality unit failed to exercise proper oversight, including oversight of your data integrity practices.” In the warning letter, the FDA noted that the Genzyme Ireland site’s quality unit didn’t make sure lab records included complete data from all necessary tests, failing to document multiple non-viable particulate excursion tests for review and investigation, among other missteps. The FDA further asserted that the Waterford facility’s laboratory records “were incomplete because quality control personnel used uncontrolled Review Checklists to unofficially document laboratory record reviews, which were subsequently discarded.” Record updates weren’t always traceable or attributable to a specific worker, either, the FDA pointed out. The agency also chided the site for failure to properly investigate manufacturing batch discrepancies or failures, including “whether or not the batch has already been distributed.” Sanofi plans to work in tandem with the FDA to meet its requirements, the company spokesperson told Fierce on Wednesday, adding that all products released from the Ireland site “meet established quality and safety specifications.” The company does “not anticipate any impact on our ability to supply medicines at this time,” per the spokesperson. The FDA reprimand comes more than a year after Sanofi's Genzyme unit received a separate warning letter at its facility in Framingham, Massachusetts, in that instance focused on subpar manufacturing error investigations and inconsistent drug ingredient production, among other problems. Sanofi acquired Genzyme way back in 2011, spending a little more than $20 billion for the company historically focused on inherited disorders, kidney diseases, cancer and transplant and immune diseases. The company was more holistically absorbed into the Sanofi corporate scheme during the French pharma’s branding overhaul in 2022.